Comparing right- versus left-first implantation in off-pump sequential double-lung transplantation: an observational cohort study

Lung Cancer

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

Lancet Respir Med

Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A

doi: 10.1016/S2213-2600(24)00417-X

Lung Cancer

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Lancet Respir Med

Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group

doi: 10.1016/S2213-2600(25)00121-3

Interstitial Lung Disease

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-centre cohort study

Eur Respir J

Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z, Fu Y, Ye Y, Lyu X, Xue Z, Wang K, Zhao J, Xie C, Chen Y, Ye C, Dai M, Fan W, Li J, Wang X, Xue Y, Wan W, Sun L, Wu H, Luo Q, Han Q, Fu Q, Ye S

doi: 10.1183/13993003.01488-2024

RECOMMENDED

Further Publications

Single Versus Double Lung Transplant in Older Adults: A Propensity-Matched Analysis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Weingarten N, Mehta AC, Budev M, Ahmad U, Yun J, McCurry K, Elgharably H

doi: 10.1016/j.chest.2024.08.044

Lung Cancer

Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results

Chest

Ezenwankwo E, Jones C, Nguyen DT, Eberth JM

doi: 10.1016/j.chest.2025.04.033

RECOMMENDED

Lung Cancer

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C, GFPC 08–2015 ENERGY investigators

doi: 10.1016/S2213-2600(24)00264-9

COPD

Comparative effectiveness and safety of escalating to triple therapy versus switching to dual bronchodilators after discontinuing LABA/ICS in patients with COPD: a retrospective cohort study

Ther Adv Respir Dis

Wu LW, Lin TC, Lin TH, Liou YJ, Tsai CL, Yang KY, Wang MT

doi: 10.1177/17534666241292242

RECOMMENDED

Further Publications

Basiliximab Induction Immunosuppression and Lung Transplant Outcomes: Propensity Analysis in a Multicenter Cohort

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Heart Lung Transplant

Rim JG, Hellkamp AS, Neely ML, Reynolds JM, Belperio JA, Budev M, Eason L, Frankel CW, Keshavjee S, Kirchner J, Singer LG, Shah PD, Snyder LD, Samuel Weigt S, Palmer SM, Todd JL

doi: 10.1016/j.healun.2024.11.033

RECOMMENDED

Interstitial Lung DiseasePneumonia

Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Valero-Martínez C, Valenzuela C, Baldivieso Achá JP, Martínez-Besteiro E, Quiroga-Colina P, Alfranca A, Vicente-Rabaneda EF, Muñiz SH, Castañeda S, García-Vicuña R

doi: 10.3390/jcm14010229

Related content

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-centre cohort study

Single Versus Double Lung Transplant in Older Adults: A Propensity-Matched Analysis

Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study

Comparative effectiveness and safety of escalating to triple therapy versus switching to dual bronchodilators after discontinuing LABA/ICS in patients with COPD: a retrospective cohort study

Basiliximab Induction Immunosuppression and Lung Transplant Outcomes: Propensity Analysis in a Multicenter Cohort

Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study